Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)
NCT ID: NCT01081158
Last Updated: 2015-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
41 participants
INTERVENTIONAL
2007-07-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)
NCT00797745
A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1
NCT01181024
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
NCT02446717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment-naïve 800 mg TID
Period 1: SCH 900518 (800 mg TID) or placebo for 7 days
Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days.
Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
Drug: SCH 900518
Biologic: Peginterferon alfa-2b(PegIntron)
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Treatment-experienced: 800 mg TID
Period 1: SCH 900518 (800 mg TID) or placebo for 7 days
Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days
Drug: SCH 900518 Biologic: Peginterferon alfa-2b
Drug: SCH 900518
Biologic: Peginterferon alfa-2b
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Treatment-naïve: 400 mg + RTV BID
Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.
Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.
Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.
Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Treatment-experienced: 400 mg + RTV BID
Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.
Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.
Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.
Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
Drug: SCH 900518
Biologic: Peginterferon alfa-2b(PegIntron)
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Drug: SCH 900518 Biologic: Peginterferon alfa-2b
Drug: SCH 900518
Biologic: Peginterferon alfa-2b
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.
Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.
Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment naïve (eg. to interferon and ribavirin); or
* treatment experienced (non-responder and relapser): subject who received interferon based therapy and continued to have detectable HCV RNA levels at the end of follow-up, a subject who did not attain a 2 log decline in HCV RNA levels at \~12 weeks and discontinued treatment, or subject who had no detectable viral load while on treatment but had a detectable viral load post treatment.
* Subject with acceptable medical history, physical examination, and clinical laboratory evaluations consistent with CHC, compensated liver disease, and any associated diseases (diabetes, hypertension, etc).
* Subjects with an HCV RNA viral load of \>10\^5 copies/mL or equivalent international units
BMI of 18 to 40 kg/m\^2, men and women, ages 18-65 years inclusive
* Female must be non-lactating and have a negative pregnancy test at Screening and Day -1 and either be of nonchildbearing potential or if of childbearing potential, must be practicing effective double-barrier contraceptive methods from at least 2 weeks prior to Day -1 until 30 days after study completion.
* Male must be willing to practice barrier contraception from Day 1 through 3 months following treatment with SCH 900518.
* Subject must have an ECG recording showing no clinically significant findings at Screening.
* Subject with chronic stable hemophilia may enroll
* Subject on stable methadone treatment may enroll in this study (evaluation by investigator includes history of stable clinical management for \>3 months).
Exclusion Criteria
* Subject has received an organ transplant.
* Subject has evidence of decompensated liver disease by physical exam (encephalopathy, ascites, caput medusae, etc).
* Subject has at anytime received an HCV NS3-specific protease inhibitor.
* Subject has a platelet count \<80,000/mm\^3 (confirmed by repeat analysis) at Screening.
* Subject has a serum hemoglobin of \<10.0 g/dL (confirmed by repeat analysis) at Screening.
* Subject has a serum AST /ALT value \>5 x ULN (confirmed by repeat analysis) at Screening.
* Subject has a serum alkaline phosphatase value \>2 x ULN (confirmed by repeat analysis) at Screening.
* Two or more of the following criteria (confirmed by repeat analysis) at Screening:
* Total serum bilirubin \>2.0 mg/dL.
* Serum albumin \<3.5 g/dL.
* INR \>1.7 (with the exception of hemophiliacs).
* Subject has a neutrophil count \<1,000/mm\^3 (confirmed by repeat analysis) at Screening.
* Creatinine clearance (as estimated by method of Cockcroft and Gault) less than 50 mL/min at Screening.
* Subject who has a history of any clinically significant local or systemic infectious disease within 1 week prior to screening (other than HCV-infection).
* Male subject whose female partner intends on becoming pregnant within 3 months of the study.
* Subject is positive for HIV antibodies or hepatitis B surface antigen.
* Subject has a clinically significant allergy or intolerance to foods or drugs, or is known or suspected to have hypersensitivity to any ingredient in the investigational product.
* Subject has a clinically significant history of auto-immune hepatitis.
* Subject has used any investigational drugs or donated blood within 30 days prior to study drug administration.
* Subject who received any of the following treatments: known inhibitor of CYP3A4 metabolism (2 weeks of prior to randomization), known inducer of CYP3A4 metabolism (2 weeks prior to randomization) and treatment for HCV infection (1 month prior to randomization)
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
de Bruijne J, Bergmann JF, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J, Tong X, Li J, Treitel MA, Hughes EA, van Lier JJ, van Vliet AA, Janssen HL, de Knegt RJ. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology. 2010 Nov;52(5):1590-9. doi: 10.1002/hep.23899.
Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HL, Reesink HW. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. J Viral Hepat. 2013 Apr;20(4):e78-81. doi: 10.1111/jvh.12012. Epub 2013 Jan 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P04695
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.